Loading...
XSHE300026
Market cap1.53bUSD
Jan 15, Last price  
3.68CNY
1D
-1.34%
1Q
-3.92%
Jan 2017
-32.23%
IPO
74.93%
Name

Tianjin Chase Sun Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:300026 chart
P/E
22.12
P/S
1.85
EPS
0.17
Div Yield, %
1.38%
Shrs. gr., 5y
-0.21%
Rev. gr., 5y
7.45%
Revenues
6.05b
-9.01%
56,223,818118,693,079187,004,412225,080,548383,878,614561,778,7871,229,251,6772,097,201,2032,863,559,6003,348,250,7473,867,017,3073,374,018,9624,223,964,7345,002,938,5386,488,115,9337,670,525,0296,650,024,8826,051,010,272
Net income
507m
-18.84%
7,362,25739,852,02964,385,83780,969,817102,028,672122,164,977231,098,259339,536,492447,012,601534,903,487658,532,190450,729,739210,795,341402,529,542573,394,032687,316,929624,241,810506,631,425
CFO
1.53b
+105.29%
1,224,28572,009,55877,735,371135,058,88346,246,00335,638,433152,213,150143,596,285149,941,309120,997,939448,078,567742,379,978388,194,758216,103,791196,661,909391,598,803745,345,6481,530,094,404
Dividend
May 23, 20240.03 CNY/sh

Profile

Tianjin Chase Sun Pharmaceutical Co.,Ltd engages in the research, development, production, and marketing of various pharmaceutical products in China. The company offers Chinese herb preparation products, medicinal granules, synthetic drugs, biotech drugs, medical apparatus, and Internet based therapy. It is also involved in the research and development of various drugs in the areas of sepsis, pulmonary hypertension, leukemia, cardiovascular and cerebrovascular diseases, arthritis, ischemic stroke, HCV, vascular disease, psychosis, and chemotherapy, as well as anesthesia drugs and immunomodulators. The company was founded in 1996 and is based in Tianjin, China.
URL
https://www.chasesun.cn/
IPO date
Oct 30, 2009
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
6,051,010
-9.01%
6,650,025
-13.30%
Cost of revenue
4,651,983
5,473,533
Unusual Expense (Income)
NOPBT
1,399,027
1,176,492
NOPBT Margin
23.12%
17.69%
Operating Taxes
105,255
95,399
Tax Rate
7.52%
8.11%
NOPAT
1,293,773
1,081,093
Net income
506,631
-18.84%
624,242
-9.18%
Dividends
(154,695)
(120,166)
Dividend yield
1.22%
0.70%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
23,175
667,310
Long-term debt
1,376,082
1,501,486
Deferred revenue
62,558
62,041
Other long-term liabilities
(2)
2
Net debt
(421,998)
560,536
Cash flow
Cash from operating activities
1,530,094
745,346
CAPEX
(347,123)
Cash from investing activities
(402,917)
Cash from financing activities
(768,495)
FCF
1,888,395
363,697
Balance
Cash
1,573,637
1,206,227
Long term investments
247,618
402,033
Excess cash
1,518,705
1,275,759
Stockholders' equity
7,990,639
7,873,422
Invested Capital
8,751,454
9,248,780
ROIC
14.38%
12.18%
ROCE
13.59%
11.17%
EV
Common stock shares outstanding
2,980,185
3,004,155
Price
4.24
-25.35%
5.68
-27.46%
Market cap
12,635,984
-25.95%
17,063,599
-27.46%
EV
12,371,685
17,796,942
EBITDA
1,745,134
1,483,290
EV/EBITDA
7.09
12.00
Interest
67,427
69,668
Interest/NOPBT
4.82%
5.92%